TRAZIMERA 440 MG — DIN 02483467
TRASTUZUMAB : 440 MG · PFIZER CANADA ULC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is TRAZIMERA?
TRAZIMERA 440 MG contains TRASTUZUMAB : 440 MG. It is listed in the Health Canada Drug Product Database under DIN 02483467, held by PFIZER CANADA ULC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 22-Oct-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRAZIMERA used for?
Trazimera (trastuzumab for injection) is indicated for: Early Breast Cancer (EBC) - the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2 - following surgery and after chemotherapy - following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. Metastatic Breast Cancer (MBC) - the treatment of patients with MBC whose tumours overexpress HER2. Metastatic Gastric Cancer (MGC) - use in combination with capecitabine or intravenous 5-fluorouracil and cisplatin for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Trastuzumab cost around the world?
Trastuzumab is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 5 | 70 | AUD███.██ |
| Saudi Arabia | public | 12 | 16 | SAR███.██ |
| Greece | producer price (ex-factory) | 15 | 15 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 7 | 15 | NOK███.██ |
| Romania | max producer price | 11 | 13 | RON███.██ |
| Italy | ex-factory (classe H) | 12 | 12 | EUR███.██ |
| Hungary | producer price (ex-factory) | 11 | 11 | HUF███.██ |
| United Arab Emirates | public | 9 | 9 | AED███.██ |
| Bahrain | retail (max) | 4 | 8 | BHD███.██ |
| Czechia | max producer price (ex-factory) | 6 | 7 | CZK███.██ |
| Slovakia | categorised final price | 7 | 7 | EUR███.██ |
| Iceland | max wholesale | 4 | 6 | ISK███.██ |
| South Africa | single exit price | 6 | 6 | ZAR███.██ |
| Morocco | PPV (public price) | 1 | 1 | MAD███.██ |
196 pack listings across 110 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Trastuzumab pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Trastuzumab in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
7 holders have a Canadian DIN containing Trastuzumab, across 14 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AMGEN CANADA INC | 2 | 2 | KANJINTI | Sourceable in Canada |
| BIOSIMILAR COLLABORATIONS IRELAND LIMITED | 2 | 2 | OGIVRI | Sourceable in Canada |
| CELLTRION INC. | 2 | 2 | HERZUMA | Sourceable in Canada |
| HOFFMANN-LA ROCHE LIMITED | 2 | 2 | HERCEPTIN, HERCEPTIN SC | Sourceable in Canada |
| PFIZER CANADA ULC | 2 | 2 | TRAZIMERA | Sourceable in Canada |
| SAMSUNG BIOEPIS CO., LTD | 2 | 2 | ONTRUZANT | Sourceable in Canada |
| ACCORD HEALTHCARE INC | 2 | 0 | ADHEROZA | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 440 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 440 mg/vial and 150 mg/vial |
| Storage | Store reconstituted Trazimera at 2°C - 8°C. When reconstituted with BWFI, discard unused Trazimera after 28 days. If SWFI is used for reconstitution, the reconstituted solution should be used as soon as possible from a microbiological point of view and no later than 48 hours after reconstitution. Any remaining reconstituted solution should be discarded. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Trastuzumab |
|---|---|
| ATC code | L01FD01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | Yes |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02483467 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2483467 |
| Brand name | TRAZIMERA |
| Generic / active ingredient | TRASTUZUMAB : 440 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Schedule D |
| ATC code | L01FD01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01FD |
| Current status | MARKETED |
| Status date | 22-Oct-2019 |
| Original market date | 2019-10-22 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 14 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| HERCEPTIN | 440 MG | POWDER FOR SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02240692 |
| HERCEPTIN SC | 600 MG / 5 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02480697 |
| HERZUMA | 440 MG | POWDER FOR SOLUTION ; KIT | CELLTRION INC. | MARKETED | 02480794 |
| HERZUMA | 150 MG | POWDER FOR SOLUTION | CELLTRION INC. | MARKETED | 02506211 |
| KANJINTI | 420 MG | KIT ; POWDER FOR SOLUTION | AMGEN CANADA INC | MARKETED | 02496690 |
| KANJINTI | 150 MG | POWDER FOR SOLUTION | AMGEN CANADA INC | MARKETED | 02518244 |
| OGIVRI | 20 ML | POWDER FOR SOLUTION | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | MARKETED | 02474433 |
| OGIVRI | 150 MG | POWDER FOR SOLUTION | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | MARKETED | 02474425 |
| ONTRUZANT | 150 MG | POWDER FOR SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | 02524317 |
| ONTRUZANT | 440 MG | POWDER FOR SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | 02524325 |
2 · Same class — other molecules in ATC L01FD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Trastuzumab | ADHEROZA · HERCEPTIN · HERCEPTIN SC · HERZUMA · +4 more | 14 | 12 | Yes |
| Trastuzumab Emtansine | KADCYLA | 2 | 2 | Yes |
| Pertuzumab | PERJETA | 1 | 1 | Yes |
| Trastuzumab Deruxtecan | ENHERTU | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01F
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01FX | Amivantamab · Belantamab Mafodotin · Blinatumomab · Brentuximab Vedotin · Catumaxomab · +19 more | 36 | 29 |
| L01FG | Bevacizumab · Ramucirumab | 14 | 14 |
| L01FF | Atezolizumab · Avelumab · Cemiplimab · Dostarlimab · Durvalumab · +3 more | 14 | 12 |
| L01FA | Obinutuzumab · Ofatumumab · Rituximab | 11 | 8 |
| L01FC | Daratumumab · Isatuximab | 5 | 5 |
| L01FY | Nivolumab And Relatlimab · Pertuzumab And Trastuzumab | 4 | 4 |
| L01FE | Cetuximab · Necitumumab · Panitumumab | 5 | 3 |
| L01FB | Inotuzumab Ozogamicin | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TRAZIMERA called?
The same molecule, Trastuzumab, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Herzuma | Latin | Australia, Bahrain, Czechia, Norway, Saudi Arabia |
| Kanjinti | Latin | Australia, Iceland, Norway, Saudi Arabia |
| Ogivri | Latin | Australia, Czechia, Norway, Saudi Arabia |
| Herceptin | Latin | Bahrain, Czechia, Iceland, Morocco, Norway |
| Zercepac | Latin | Czechia, Iceland, Norway, Saudi Arabia |
| Herceptin SC | Latin | Australia |
| Ontruzant | Latin | Czechia, Norway, Saudi Arabia |
| CANHERA | Latin | Bahrain, Saudi Arabia |
| Enhertu | Latin | Saudi Arabia |
| Equituz | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.